NORWALK, Conn.

诺沃克，康涅狄格州

,

，

May 18, 2026

2026年5月18日

/PRNewswire/ -- Lifespan Vision Ventures (LVV), an investment firm focused on therapeutics that improve human healthspan, today announced that it has led Violet Therapeutics' $4.75 million seed extension financing, with participation from Dementia Discovery Fund, UTEC, Ono Venture Investment, and Mass General Brigham Ventures..

/PRNewswire/ -- 致力于改善人类健康寿命的治疗投资公司Lifespan Vision Ventures (LVV) 今日宣布，其已领投Violet Therapeutics 475万美元的种子扩展轮融资，参投方包括痴呆症发现基金、UTEC、小野风险投资以及Mass General Brigham Ventures。

Violet Therapeutics is a preclinical-stage biotechnology company developing first-in-class therapies for neurodegenerative disease by mapping disease-relevant cell-to-cell signaling interactions in the brain. The company's proprietary CONNECT platform is designed to identify therapeutically actionable signaling pathways that drive neuroinflammation, neurodegeneration, and synaptic loss..

Violet Therapeutics是一家处于临床前阶段的生物技术公司，通过绘制大脑中与疾病相关的细胞间信号传导相互作用，开发针对神经退行性疾病的首创疗法。该公司专有的CONNECT平台旨在识别驱动神经炎症、神经退行性和突触丧失的治疗可操作信号通路。

Synaptic loss is one of the strongest predictors of cognitive decline in Alzheimer's disease and other neurodegenerative conditions, and Violet's lead program is designed to address this core pathology through glial-mediated synaptic preservation and repair. 'Preserving cognitive function is one of the most important challenges in aging biology, and Violet is approaching that challenge from a uniquely actionable angle,' said Altar Munis, Associate at Lifespan Vision Ventures.

突触丧失是阿尔茨海默病和其他神经退行性疾病中认知能力下降的最强预测因素之一，而Violet的主导项目旨在通过胶质细胞介导的突触保护和修复来应对这一核心病理。Lifespan Vision Ventures的助理Altar Munis表示：“保持认知功能是衰老生物学中最重要的挑战之一，而Violet正从一个极具可行性的角度来应对这一挑战。”

'The company's CONNECT platform gives it a systematic way to uncover how glial signaling contributes to synaptic dysfunction, with EphB3 representing a strong first step toward therapies that may protect brain health across aging and neurodegenerative disease.'.

“该公司的CONNECT平台使其能够系统地揭示胶质信号传导如何导致突触功能障碍，而EphB3代表了迈向可能保护衰老和神经退行性疾病中大脑健康的疗法的坚实第一步。”

'We are pleased to welcome LVV as the lead investor in this extension round. LVV brings deep sector expertise in technologies that will impact diseases of aging and cognition. Likewise, their addition to the board adds valuable perspective as we continue to advance our EphB3 program towards the clinic and to develop our CONNECT discovery platform,' said Meredith Fisher, Partner at Mass General Brigham Ventures and CEO of Violet..

“我们很高兴欢迎LVV作为此扩展轮融资的领投方。LVV在影响衰老和认知疾病的技术领域拥有深厚的专业知识。同样，他们加入董事会为我们继续推进EphB3项目进入临床以及开发我们的CONNECT发现平台提供了宝贵的观点。” Mass General Brigham Ventures合伙人兼Violet首席执行官Meredith Fisher表示。

Proceeds from the financing will support advancement of Violet's lead small molecule program targeting EphB3 through key IND-enabling activities. EphB3, a receptor tyrosine kinase implicated in microglia-astrocyte signaling, emerged directly from Violet's CONNECT platform and represents the company's first therapeutic target generated from its cellular connectome approach..

融资所得将支持Violet推进其针对EphB3的主要小分子项目，完成关键的IND所需活动。EphB3是一种与小胶质细胞-星形胶质细胞信号传导相关的受体酪氨酸激酶，直接源自Violet的CONNECT平台，代表了公司通过细胞连接组方法生成的首个治疗靶点。

About Lifespan Vision Ventures

关于Lifespan Vision Ventures

Lifespan Vision Ventures is a global venture capital firm investing in early-stage biotechnology companies developing breakthrough technologies to prevent and treat age-related diseases. The firm partners with visionary founders advancing science-driven solutions that promote healthy aging and extend human healthspan..

Lifespan Vision Ventures 是一家全球风险投资公司，专注于投资开发突破性技术以预防和治疗与年龄相关疾病的早期生物技术公司。该公司与富有远见的创始人合作，推动促进健康老龄化和延长人类健康寿命的科学驱动型解决方案。

Contact:

联系人：

[email protected]

电子邮件地址

About Violet Therapeutics

关于Violet Therapeutics

Violet Therapeutics is a preclinical-stage biotechnology company developing first-in-class therapies for neurodegenerative disease by mapping disease-relevant cell-to-cell signaling interactions in the brain. The company's proprietary CONNECT platform enables discovery of novel targets emerging from cellular interaction networks rather than genetic association alone, supporting the development of a pipeline of small-molecule therapeutics addressing neuroinflammation and related CNS pathologies..

Violet Therapeutics是一家处于临床前阶段的生物技术公司，通过绘制大脑中与疾病相关的细胞间信号传导相互作用，开发针对神经退行性疾病的首创疗法。该公司专有的CONNECT平台能够发现来自细胞交互网络的新靶点，而不仅仅是基于基因关联，从而支持针对神经炎症及相关中枢神经系统病理的小分子治疗药物的研发管线。

For more information, visit

欲了解更多信息，请访问

www.violettx.com

www.violettx.com

Media contact:

媒体联系人：

Meredith Fisher, CEO

梅雷迪思·费舍尔，首席执行官

[email protected]

电子邮件地址

SOURCE LifeSpan Vision Ventures

来源：LifeSpan Vision Ventures

21

21

%

%

more press release views with

更多新闻发布视图与

Request a Demo

请求演示